IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.14
+2.15%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$386.60M
MomentumView details →
1D Return
+2.15%
YTD Return
+113.61%
RSI (14)
52.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$386.60M
RSI (14)
52.6
MomentumView details →
1D Return
+2.15%
YTD Return
+113.61%
SummaryUpdated Jun 1, 2026
Century Therapeutics, Inc. (NASDAQ:IPSC) is a biotechnology company founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company went public in June 2021 and focuses on developing innovative cancer treatments using induced pluripotent stem cell (iPSC) technology. Century Therapeutics represents a next-generation approach to cell therapy, aiming to create "off-the-shelf" treatments that could potentially overcome the limitations of traditional personalized cell therapies.
Similar companies
Latest newsMore news →
Century Therapeutics is on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion 5.0, into the clinic this year.23d agoCentury Therapeutics completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, and plans to submit an IND in the fourth quarter of 2026.23d ago